How information about the time requirements and legacy effects of treatments influence decision-making in patients with diabetes and hypertension
BMJ Open Diabetes Research and Care, ISSN: 2052-4897, Vol: 4, Issue: 1, Page: e000210
2016
- 5Citations
- 25Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef3
- Captures25
- Readers25
- 25
- Mentions1
- Blog Mentions1
- Blog1
Most Recent Blog
Delayed benefits of diabetes, blood pressure medications can discourage patients
It can take up to 10 years before patients see the long-term benefits from taking medications for diabetes and high blood pressure. For some, knowing this made them less likely to start treatment. It’s easy to justify taking medications with an immediate, cause-and-effect benefit. You have strep throat, so you take an antibiotic and start to feel better within a few days, or you take aspirin to ea
Article Description
Objective: When deciding about diabetes treatments, patients are typically uninformed about how much time is required before (time requirements), or for how long treatments change outcomes (legacy effects). However, patients may be motivated to adopt treatments with time-related treatment information. We explored whether this information alters a patients’ likelihood of starting medications. Research design and methods: We conducted semistructured interviews with 60 adults with type 2 diabetes for <10 years and hypertension on oral medications. We measured change in likelihood of starting medications after receiving time requirement (diabetes, 10 years; hypertension, 3 years) and legacy effect (diabetes, 10 additional years; hypertension, none) information. Responses were analyzed for themes about time-related treatment information. Results: At baseline, 70% of participants reported being very likely to start a recommended medication. Nearly half (40%) were less likely to start a diabetes medication after being informed of time requirements; but after being informed of legacy effects, 32% reported being more likely. Fewer participants changed likelihoods of starting antihypertensives with time-related information. Many participants expressed that medications’ benefits were important to them regardless of time-related information. Participants considered time requirements for diabetes medications too long and compared them to their life expectancy. Many participants were interested in legacy effects of diabetes medications because they looked forward to discontinuing medications, although some expressed doubt that benefits could persist after stopping medications. Conclusions: While prolonged time requirements may dissuade patients from adopting treatments, the promise of legacy effects may motivate patients to commit to diabetes treatments.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84991518393&origin=inward; http://dx.doi.org/10.1136/bmjdrc-2016-000210; http://www.ncbi.nlm.nih.gov/pubmed/27158521; https://drc.bmj.com/lookup/doi/10.1136/bmjdrc-2016-000210; https://dx.doi.org/10.1136/bmjdrc-2016-000210; https://drc.bmj.com/content/4/1/e000210
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know